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Renal transplantation is the treatment of choice for the patients with end-stage renal 
failure. Genetic factors, among others, can influence variability in response to immuno-
suppressive drugs. Nowadays, due to restrictive health resources, the question arises 
whether routine pharmacogenetic analyses should be done in the renal transplant recip-
ients or not. The aim of this literature review was to present the up-to-date information 
considering the economic feasibility of pharmacogenetic testing in patients subjected 
to renal transplantation. The organization United Network for Organ Sharing in the US 
estimated that total costs per renal transplant concerning these analyses were $334,300 
in 2014. Pharmacogenetic testing prior to treatment initiation could be helpful to predict 
and assess treatment response and the risks for adverse drug reactions. This kind of 
testing before treatment initiation seems to be one of the most promising applications of 
pharmacokinetics. Although pharmacogenetic tests were found to be a cost-effective or 
cost-saving strategy in many cases, some authors represent another opinion. However, 
if the real costs of renal transplantation are recognized, the application of these tests 
in the standard daily practice could be considered more realistic, which additionally 
emphasizes the importance of future studies assessing their cost effectiveness.
Keywords: health economics, genetic polymorphisms, renal transplantation, pharmacogenetic tests, 
immunosuppressive drugs
inTRODUCTiOn
End-stage renal disease is the last stage of the chronic renal disease. The most common causes of 
end-stage renal disease are diabetes and high blood pressure (1–3). In the general population, the 
prevalence of chronic renal disease varies approximately from 7 to 20% (4–8). Dialysis (hemodialysis 
and peritoneal dialysis) and renal transplantation are the treatments for the patients with end-stage 
renal failure. Renal transplantation is the treatment of choice for these patients since survival rate and 
quality of life are better in comparison to patients who are subjected to dialysis (9, 10).
According to US statistics, chronic kidney disease afflicted up to 20 million people, while more 
than 871,000 of patients were being treated for end-stage renal diseases in 2009 (11, 12). Also, 17,107 
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renal transplants were performed in 2014. Moreover, 100,791 
people are currently estimated to be waiting for renal transplants 
(13). Pre-end-stage renal disease entails a cost in excess of $26,000 
per patient per year (12). The World Health Organization, as the 
leading authority, is seriously concerned about these figures.
The major problems in renal transplantation are: the shortage of 
donors, adequate immunosuppression, allograft dysfunction and 
rejection, adverse reactions to drugs, therapeutic drug monitoring 
(TDM), restricted health resources, etc. However, the problems of 
greatest concern are the prevention of graft rejection and chronic 
toxicity of immunosuppresants due to their inadequate levels in 
the plasma. The inter- and intraindividual variability in response 
to immunosuppressive drugs is well known (14, 15). Gender, 
age, body mass index, hematocrit, diabetes status, liver dysfunc-
tion, drug interactions, etc., can also influence the variability in 
response to these drugs among patients (14, 16). In addition, 
genetic factors are likely to play a major role as well (17, 18).
Personalized medicine refers to the application of patient-
specific profiles (incorporating genetic and genomic data) in 
order to assess individual risks and tailor prevention and disease-
management strategies (19, 20). Therefore, a better control of 
immunosuppression should be achieved by pharmacogenetic 
testing (21).
Current recommended immunosuppression protocols in the 
patients subjected to renal transplantation include a combina-
tion of calcineurin inhibitors (tacrolimus or cyclosporine) and 
antiproliferative agents (mycophenolate mofetil or azathioprine), 
with and without regimens of corticosteroids (18, 22, 23). 
Tacrolimus as the first-line treatment is recommended by the 
Kidney Disease Improving Global Outcomes Transplant Work 
Group (KDIGO) (23). Mammalian target of rapamycin (mTOR) 
inhibitors (everolimus or sirolimus) should be used instead of 
calcineurin inhibitors but only after the graft function has been 
established and surgical wounds have healed (23). Induction 
therapy (interleukin 2 receptor antagonists) is used in high-
immunological risk renal transplant recipients.
Gene polymorphism as a significant factor contributes to 
the variability in pharmacokinetics and pharmacodynamics of 
immunosuppressive drugs, which may result in their toxicity 
and/or lack of efficacy (14, 15, 24, 25). Therefore, pharmacoge-
netic analyses could be very important for immunosuppressive 
drug therapy. However, due to the restriction of health resources, 
the question arises whether renal transplantation management 
should include routine pharmacogenetic testing.
The aim of our study was to determine the economic feasibil-
ity of pharmacogenetic analyses in patients subjected to renal 
transplantation based on a review of relevant literature.
THe iMPACT OF GeneTiC 
POLYMORPHiSMS On THe MeTABOLiSM 
AnD TRAnSPORT OF 
iMMUnOSUPPReSSive DRUGS
The TDM of immunosuppressive drugs helps the determination 
of suitable dose, and the trial and error approach to dosing is 
still a common everyday practice. Nowadays, the challenge is to 
combine pharmacogenetic with pharmacokinetic information in 
order to provide patients with the most suitable treatment.
Many pharmacogenetic studies have been conducted to evalu-
ate the importance of genetic polymorphism for tacrolimus and 
cyclosporine therapy success, mostly in regard to CYP3A4/5 and 
P-glycoprotein (P-gp). The most prominent gene-dependent 
effect on tacrolimus pharmacokinetics has been observed for 
CYP3A5 (26). CYP3A5 activity differs significantly among indi-
viduals, which is mainly due to its genetic polymorphism: those 
who have at least one wild-type allele (CYP3A5*1) are denoted 
as expressors, and homozygote carriers of non-functional alleles, 
such as CYP3A5*3, as non-expressors (27). Numerous studies 
on tacrolimus pharmacokinetics in transplant recipients consist-
ently reported that carriers of CYP3A5*3/*3 genotype require 
significantly lower doses for both induction and the maintenance 
phase of the therapy (28–38). Similar effects of CYP3A5 polymor-
phism on cyclosporine levels have been detected, but the reports 
remained largely inconsistent (29, 37, 39–41).
Although wide interindividual variations in CYP3A4 levels 
have been described (42), only few gene polymorphisms have 
been associated with altered in vivo enzyme activity (43, 44). In 
renal transplant patients, significantly lower daily tacrolimus dose 
requirements were observed in carriers of CYP3A4*18 and *22 
alleles (41, 45–47), especially in CYP3A5 non-expressors (48–50). 
The same, but usually less, pronounced effect was detected in 
transplant recipients on cyclosporine therapy (40, 47, 48). On the 
other hand, CYP3A4*1B have been associated with higher tac-
rolimus dose requirements (51, 52), but the conclusions remained 
arguable, mainly due to the strong linkage disequilibrium between 
this CYP3A4 allele and fully functional CYP3A5*1 (29).
P-glycoprotein is an efflux transporter involved in elimina-
tion and permeability restriction of numerous endogenous and 
xenobiotic compounds, including calcineurin inhibitors (53, 54). 
It is encoded by the highly polymorphic ABCB1 (MDR1) gene, 
with more than 250 non-synonymous single nucleotide polymor-
phisms (SNPs) described so far (54). Of those, the most frequent 
and thus most extensively studied are 1236C > T, 2677G > T/A, 
and 3435C > T (53, 54). In the renal transplant recipients that do 
not express CYP3A5, 1236–2677–3435 TTT-TTT diplotype was 
highly associated with lower tacrolimus dose requirements (38), 
and similar effect was observed when individual ABCB1 poly-
morphisms were considered (55–57). In patients on cyclosporine 
therapy, significantly higher daily dose requirements were found 
in 2677GG and 3435CC genotype carriers (58, 59). However, 
there are studies that failed to find any significant association 
between pharmacogenetics of P-gp and pharmacokinetics of cal-
cineurin inhibitors (60–62); therefore, the proposed relationship 
is still considered controversial.
Inhibitors of mTOR are substrates for CYP3A4/5 and CYP2C8 
enzymes and P-gp (63). However, pharmacogenetic studies in 
regard to sirolimus and everolimus treatment are scarce and with 
conflicting results. In renal transplant recipients, significantly 
higher sirolimus dose requirements were observed in carriers of 
CYP3A4*1B allele or in the absence of CYP3A5*3, while ABCB1 
polymorphism did not affect drug pharmacokinetics (64–66). 
The effect of CYP3A5*3 on everolimus was investigated, but not 
detected (67, 68).
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Based on a considerable body of evidence in favor of  clinically 
relevant genotype–phenotype association, a guideline for 
CYP3A5 genotype and tacrolimus dosing was published (69). 
In regard to other calcineurin and mTOR inhibitors and their 
disposition-related genes, there are currently not enough data to 
support routine pharmacogenetic testing (70).
Azathioprine is a precursor of 6-mercaptopurine (6-MP), 
further metabolized to active thioguanine nucleotide (TGN) 
metabolites through a multi-step process (71, 72). Glutathione 
S-transferase has been implicated in the formation of 6-MP, which 
is then inactivated in the liver by highly polymorphic thiopurine 
S-methyltransferase (TPMT), as well as by xanthine oxidase (73). 
Heterozygous and homozigous carriers of non-functional TPMT 
alleles (mainly *2, *3A, *3B, *3C, and *4) have low and deficient 
enzyme activity, respectively, and are at significantly higher risk of 
adverse drug reactions to azathioprine (73–76). Thus, the routine 
genotyping for TPMT polymorphisms prior to the initiation 
of the therapy has become a cornerstone of thiopurines-based 
treatment (77).
Mycophenolat mofetil is another prodrug, which requires 
enzymatic hydrolysis for activation (78). Mycophenolic acid 
then undergoes further biotransformation, which includes glu-
curonidation as the major metabolic pathway. Several uridine 
5′-diphospho glucuronosyl transferases (UGTs) are involved 
in the process. However, UGT1A9 is of special importance, 
as certain SNPs of its coding gene, as well as of the genes 
coding for drug transporters (such as SLCO1B1), lead to a 
significantly lower drug exposure and a higher risk of acute 
transplant rejection (79, 80). In addition, the gene coding for 
inosine monophosphate dehydrogenase (IMPDH), the target 
of mycophenolic acid, is also polymorphic, and the association 
of certain IMPDH SNPs with the immunosuppressive response 
were reported (81). However, the data on the impact of genet-
ics on the drug efficacy and safety are still conflicting (70, 78), 
Therefore, currently, there are no recommendations for routine 
pharmacogenetic testing in regard to mycophenolat mofetil 
therapy.
In regard to the use of biologic agents and corticosteroids in 
induction and maintenance therapy, no evidence showing the 
association between genetic polymorphisms and their pharma-
cokinetics or pharmacodynamics was found in the literature (82).
THe eCOnOMiC evALUATiOn OF RenAL 
TRAnSPLAnTATiOn
The history of health economics in recent decades (83) teaches 
us that the burden of non-communicable “prosperity” illnesses 
is among the top causes of growing costs of health care (84). 
This landscape of medical care spending has evolved consider-
ably across the Globe with developing and emerging economies 
taking ever larger share of global expenditure on health (85). 
This fact is taking its toll since the Third World nations are 
facing double burden: the old unresolved pool of infectious 
diseases and another rapidly expanding one attributable to the 
non-communicable diseases (NCD) (86). Coping with the chal-
lenges outsourcing from cancer, diabetes, fertility issues, mental 
disorders, and ultimately renal failure, thus, is made substantially 
more difficult. These systems were traditionally shaped to combat 
acute communicable diseases and injuries at the first place (87). 
Now they face chronic illnesses, which are far more demanding 
in terms of social capital and medical resources that need to be 
devoted (88). Among the few bright success stories in lessening 
the grip of major NCDs are certainly the BRICS nations (89). 
Such change of morbidity has clearly reflected on the demand 
for pharmaceuticals and national spending on medicines in a 
large number of countries (90, 91). In case of immunosuppres-
sants used in renal transplantation procedures, this growth was 
significant both in prescription and value-based terms (92). 
Surgical services, imaging diagnostics, and home-based care, 
next to dialysis, should not be forgotten as major cost drivers in 
terminal renal failure treatment.
Nowadays, a renal transplantation is considered the treatment 
of choice for many people with severe chronic kidney disease, but 
there is a shortage of organs available for donation. Many people 
who are candidates for kidney transplantation are just put on a 
transplant list to wait for an available organ. However, the waiting 
time on the list may vary considerably.
The costs of renal transplantation include transplant 
evaluation and testing, transplant surgery, follow-up care, and 
medication. After a renal transplantation, patients will need 
several drugs, including immunosuppressants, to sustain the 
transplanted kidney. Costs per one transplant patient in Serbia 
for a 10-year period were calculated to be €48,949 (93). On the 
other hand, according to the US United Network for Organ 
Sharing (UNOS), the first year billed charges for a kidney 
transplant are more than $262,000 (94). The total monthly 
costs of Cellcept®, Prograf®, Prednisone®, and Myfortic® are 
approximately $1,064, $1,340, $12, and $806, respectively. The 
2-year costs of four different immunosuppressive strategies 
(sirolimus, everolimus, cyclosporine, or tacrolimus) have been 
shown to vary between €26,732 and €49,978 (95). Therefore, in 
the time of restricted health resources, the choice of therapy is 
very important.
Renal transplantation costs differ significantly worldwide. 
For example, the total cost of renal transplantation procedure 
in Iran was $9,224 (96). The immunosuppressive therapy 
accounted for 65.8% ($6,076), only in the first year. The trans-
plantation procedure costs were $2,048, while organ procure-
ment was about $1,100. On the other hand, the total costs of 
the first year after transplantation in Sudan were US$14,825 and 
after that approximately US$10,651 (97). The renal transplant 
cost estimate in India was about US$70,000 for laparoscopic 
kidney transplantation, while open nephrectomy costs were 
US$100,000 (98). In the US, laparoscopic kidney transplanta-
tion and open nephrectomy cost approximately US$300,000 and 
US$450,000, respectively.
Cost estimates of UNOS per renal transplant concerning 
30  days pre-transplantation, procurement, hospital transplant 
admission, physician services during transplant, 180-days post-
transplant, and administration of immunosuppressants in 2011 
and 2014 in the US are represented in Figure 1 (99). The total 
costs were $262,900 and $334,300 in 2011 and 2014, respectively 
(99–101).
FiGURe 1 | The costs of renal transplantation in 2011 and 2014 according to the US United network for Organ Sharing (UnOS).
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THe eCOnOMiC evALUATiOn OF 
PHARMACOGeneTiC TeSTS
Pharmacogenetic testing prior to the treatment initiation could 
be helpful to assess both the risks of adverse drug reactions and 
treatment response (21, 102). Moreover, pharmacogenetics-based 
testing before treatment initiation seems to be one of the most 
promising applications of drug pharmacokinetics.
The cost effectiveness of genotyping prior to the therapy with 
some drugs, such as abacavir, allopurinol, carbamazepine, clopi-
dogrel, and irinotecan, indicates that genotyping was justified 
when it was performed on a large numbers of patients. However, 
evaluation of cost effectiveness of genotyping prior to the use of 
immunosuppressive drugs has not been performed yet.
Provenzani et  al. concluded that, considering the relatively 
high costs of pharmacogenetic tests and availability of TDM, the 
genotyping of all transplant patients is not affordable in many 
countries (103). This situation may change in the near future 
since studies on pharmacogenetics would produce valuable data, 
and the improvements in the genotyping analyses will decrease 
the costs associated with this type of tests. However, prospective 
clinical studies must show that genotype determination before 
transplantation allows for the better use of given drugs and 
improves their safety and clinical efficacy. Currently, genetic tests 
determining a patient’s CYP2D6 and CYP2C19 polymorphisms 
cost from $350 to $400, not including the markup and some other 
costs associated with the test. Moreover, most genetic tests cost 
a few hundred dollars at the moment, but they are estimated 
to become less expensive in the future (104–106). However, to 
justify the costs of genetic testing, genotypic analyses have to 
demonstrate their ability to significantly improve transplant 
patient outcomes and show cost savings.
The pharmacogenetic tests prior to the treatment with 
azathioprine represent a good example of saving money. The 
cost-effectiveness model for azathioprine, based on parameters 
collected for TPMT genotyping costs, estimates for frequency 
of TMPT deficiency, rates of thiopurine-mediated myelosup-
pression in TPMT-deficient individuals, and myelosuppression-
related hospitalization costs, established that TPMT testing in all 
patients had a favorable cost-effectiveness ratio (107). The costs 
of a genotype test were estimated on about $NZ30 (€18.90) (108). 
In another study, it was estimated that costs of the TPMT screening 
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(genotype) were $510.06 (109). These authors concluded that the 
least costly treatment strategy was TPMT screening, with 1-year 
costs saving per patient of $3,281. The mean calculated cost 
per life year, gained by TPMT genotyping in all patients in the 
four studied countries (Germany, Ireland, Netherlands, and the 
United Kingdom), was €2,100, based on genotyping costs of €150 
per patient (107).
Thervet et  al. have recommended a successful protocol of 
tacrolimus starting dose determined by patient’s genotype: 
CYP3A5*3*3 are to be given 0.15 mg/kg/day, while CYP3A5*1*1 
or *1*3 expressers should be treated with 0.30 mg/kg/day (110). On 
the base of this protocol, in the group receiving the adapted dose, 
a higher proportion of patients had values within the targeted C0 
on day 3 after the initiation of tacrolimus. Namely, they required 
fewer dose modifications while the targeted C0 was achieved by 
75% of these patients more rapidly. This pharmacogenetic test 
prior to tacrolimus initiation could be helpful to reduce the risks 
of adverse drug reactions due to the patient overexposure, as well 
as to reduce the costs due to the faster achievement of the optimal 
tacrolimus concentrations.
The substantial increase of health expenditure, due to the rapid 
population growth and aging became a great concern for gov-
ernments all over the world (111, 112). On the one hand, while 
extensive literature on the determinants of health expenditure in 
the Organization for economic co-operation and development 
(OECD) countries can be found, that is not the case with the situ-
ation in developing countries (101). Literature data show great 
variations between countries concerning health expenditure, 
since gross domestic product share ranges from 5 to 15%. For 
example, health expenditure per capita of US$9,715 in Norway 
is the biggest, while US$13 in the Central African Republic is the 
smallest.
There are many factors that account for the enormous costs of 
pharmacogenetic analyses. Devices themselves, with the current 
price of about $10,000, together with trained staff necessary to 
perform analyses, are the most expensive ones. It is obvious that 
these costs are high even for the developed countries, whereas 
for the developing countries, they are unaffordable for the time 
being (113).
COnCLUSiOn
Due to the lack of appropriate cost-effectiveness studies, and the 
availability of TDM analyses, from an economic point of view, we 
could neither recommend nor discourage the use of pharmaco-
genetic tests as a routine clinical practice in the everyday treat-
ment of renal transplant patients. Future recommendations will 
depend on robust clinical evidence regarding pharmacogenetic 
test efficacy and precise costs concerning renal transplantation.
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